GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » THC Therapeutics Inc (OTCPK:THCT) » Definitions » Capex-to-Revenue

THC Therapeutics (THC Therapeutics) Capex-to-Revenue : 0.00 (As of Jul. 2023)


View and export this data going back to 2007. Start your Free Trial

What is THC Therapeutics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

THC Therapeutics's Capital Expenditure for the three months ended in Jul. 2023 was $0.00 Mil. Its Revenue for the three months ended in Jul. 2023 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


THC Therapeutics Capex-to-Revenue Historical Data

The historical data trend for THC Therapeutics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

THC Therapeutics Capex-to-Revenue Chart

THC Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

THC Therapeutics Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of THC Therapeutics's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, THC Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


THC Therapeutics's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, THC Therapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where THC Therapeutics's Capex-to-Revenue falls into.



THC Therapeutics Capex-to-Revenue Calculation

THC Therapeutics's Capex-to-Revenue for the fiscal year that ended in Jul. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

THC Therapeutics's Capex-to-Revenue for the quarter that ended in Jul. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


THC Therapeutics  (OTCPK:THCT) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


THC Therapeutics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of THC Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


THC Therapeutics (THC Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11700 W Charleston Boulevard, No. 73, Las Vegas, NV, USA, 89135
Website
THC Therapeutics Inc is a United States-based company. It is focused on developing dHydronator, a sanitizing herb dryer. The main function of the dHydronator is to accelerate the drying time of an herb while sanitizing it. The dHydronator can be used to dry a variety of herbs, and it has been specifically tested for use with cannabis. It will reduce the drying time for cannabis from 10-14 days down to less than 14 hours.
Executives
Hiro Tanaka director, officer: Vice President 3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Smith Adrian J R director, officer: Chair of the Board 119 SPRINGLINE DRIVE, VERO BEACH FL 32963
Jamie Mann director, 10 percent owner, officer: CEO, CFO 3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Eden Ho director, officer: CEO 701 XUANG MI HU ROAD, XI YUAN, FUTIAN, SHENZHEN F4 XXXXXX